Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  lintuzumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDL-3-251, MSKCC-93131, NCI-V94-0469
Phase II Study of MOAB HuG1-M195 in Patients with Chronic Myelogenous Leukemia in Chronic or Accelerated Phase (Summary Last Modified 06/94)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 12 and over
Sponsor:
Protocol IDs: MSKCC-93111, NCI-V94-0350
Phase II Study of MOAB HuG1-M195 for Acute Promyelocytic Leukemia in TRA-Induced Remission (Summary Last Modified 07/94)
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 12
Sponsor:
Protocol IDs: MSKCC-93117, NCI-V94-0359
Phase II Study of MOAB HuM195/IL-2 for Relapsed or Refractory Myeloid Leukemia (Summary Last Modified 05/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 16
Sponsor:
Protocol IDs: MSKCC-95009, NCI-V95-0631
Phase II Randomized Study of Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (Summary Last Modified 12/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-97103, PDL-3-201, NCI-G97-1367
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068076, P30CA016042, UCLA-9910096, PDL-195-302, NCI-G00-1823, NCT00006084
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 00-072, MSKCC-00072, NCI-H01-0073, NCT00016159
Phase II Study of the Anti-CD33 Monoclonal Antibody HuG1-M195 plus IL-2 in Patients with Myeloid Leukemia (Summary Last Modified 02/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor:
Protocol IDs: MSKCC-93083, NCI-V93-0315
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Phase: Phase II
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SG033-0003, NCT00528333
Phase Ib Study of High-Dose MOAB HuM195 in Myeloid Malignancies (Summary Last Modified 11/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 12 and over
Sponsor: Other
Protocol IDs: MSKCC-95043, NCI-V95-0709
Phase I Study of MOAB HuM195 with Subcutaneous and Intravenous IL-2 in Relapsed or Refractory Myelogenous Leukemia (Summary Last Modified 03/98)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MSKCC-96003A1, NCI-T95-0026H, T95-0026
Phase I Study of Bismuth-213-Labeled Humanized Monoclonal Antibody HuM195 in Advanced Myeloid Malignancies (Summary Last Modified 01/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: MSKCC-96014A1, NCI-H96-1101
Phase IB Trial of Monoclonal Antibody HuG1-M195 in Patients with Myelogenous Leukemia (Summary Last Modified 11/92)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 12
Sponsor:
Protocol IDs: MSKCC-92088, NCI-V92-0130
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: DM98-342, NCT00038051
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SG033-0001, NCT00283114
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SG033-0002, NCT00502112
Start Over